Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Citi
Harvard Business School
McKinsey
Medtronic
Merck
Mallinckrodt
Argus Health
Accenture

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,087,613

« Back to Dashboard

Which drugs does patent 7,087,613 protect, and when does it expire?

Patent 7,087,613 protects TARCEVA and is included in one NDA.

Protection for TARCEVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in thirty-seven countries.
Summary for Patent: 7,087,613
Title:Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
Abstract:A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.
Inventor(s): Norris; Timothy (Gales Ferry, CT), Raggon; Jeffrey W. (North Stonington, CT), Connell; Richard D. (East Lyme, CT), Moyer; James D. (East Lyme, CT), Morin; Michael J. (Waterford, CT), Kajiji; Shama M. (Mystic, CT), Foster; Barbara A. (Mystic, CT), Ferrante; Karen J. (East Greenwich, RI), Silberman; Sandra L. (Randolph, NJ)
Assignee: OSI Pharmaceuticals, Inc. (Melville, NY)
Application Number:10/992,266
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,087,613
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,087,613

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-001 Nov 18, 2004 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-002 Nov 18, 2004 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Osi Pharms TARCEVA erlotinib hydrochloride TABLET;ORAL 021743-003 Nov 18, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,087,613

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,900,221 Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,087,613

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1434 ➤ Sign Up
Argentina 035563 ➤ Sign Up
Austria 420645 ➤ Sign Up
Australia 1762101 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Accenture
Boehringer Ingelheim
Julphar
Harvard Business School
Express Scripts
Argus Health
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.